Literature DB >> 8661959

Casodex (a nonsteroidal antiandrogen) reduces cancellous, endosteal, and periosteal bone formation in estrogen-replete female rats.

C Lea1, N Kendall, A M Flanagan.   

Abstract

Testosterone has been implicated in the preservation of the skeleton in women and female rats. In this study we investigated the role of androgens in estrogen-replete female rats by giving Casodex (pure nonsteroidal anti-androgen) daily and analyzing the effects on the skeleton using static and dynamic histomorphometric parameters after 3 weeks. There was a significant reduction in the bone formation rate in both the cancellous bone of the tibial metaphysis and in the periosteal and corticoendosteal diaphyseal bone (90%, 30%, and 100% reduction, respectively), compared with control animals, which was unaccompanied by a change in the indices of bone resorption. Casodex had no effect on cancellous bone volume and cortical bone area but this can be accounted for by the short duration of the experiment. The serum levels of dehydroepiandrosterone-sulfate and androstenedione were significantly reduced in the Casodex-treated rats compared with the control animals and there was no difference in the plasma levels of estrone, estradiol, or testosterone between the two groups. This study demonstrates that androgens play a physiological role in regulating osteoblast activity in female rats.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8661959     DOI: 10.1007/bf02508647

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  39 in total

1.  17 beta-estradiol stimulates cancellous bone formation in female rats.

Authors:  J W Chow; J M Lean; T J Chambers
Journal:  Endocrinology       Date:  1992-05       Impact factor: 4.736

2.  Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells.

Authors:  B S Komm; C M Terpening; D J Benz; K A Graeme; A Gallegos; M Korc; G L Greene; B W O'Malley; M R Haussler
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

3.  Relative contributions of aging and estrogen deficiency to postmenopausal bone loss.

Authors:  L S Richelson; H W Wahner; L J Melton; B L Riggs
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

4.  "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.

Authors:  B J Furr
Journal:  Horm Res       Date:  1989

5.  Effect of body weight on osteopenia in ovariectomized rats.

Authors:  T J Wronski; P A Schenck; M Cintrón; C C Walsh
Journal:  Calcif Tissue Int       Date:  1987-03       Impact factor: 4.333

6.  Progressive cancellous bone loss in rats after adrenalectomy and oophorectomy.

Authors:  T C Durbridge; H A Morris; A M Parsons; I H Parkinson; R J Moore; S Porter; A G Need; B E Nordin; B Vernon-Roberts
Journal:  Calcif Tissue Int       Date:  1990-12       Impact factor: 4.333

7.  The use of flutamide in the management of hirsutism.

Authors:  M Marugo; D Bernasconi; M Meozzi; P Del Monte; V Zino; P Primarolo; B Badaracco
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

8.  Temporal relationship between bone loss and increased bone turnover in ovariectomized rats.

Authors:  T J Wronski; M Cintrón; L M Dann
Journal:  Calcif Tissue Int       Date:  1988-09       Impact factor: 4.333

9.  The effects of ovariectomy and 17 beta-estradiol on cortical bone histomorphometry in growing rats.

Authors:  R T Turner; J J Vandersteenhoven; N H Bell
Journal:  J Bone Miner Res       Date:  1987-04       Impact factor: 6.741

10.  The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats.

Authors:  A Gallagher; T J Chambers; J H Tobias
Journal:  Endocrinology       Date:  1993-12       Impact factor: 4.736

View more
  3 in total

1.  Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats.

Authors:  Jeffrey D Kearbey; Wenqing Gao; Ramesh Narayanan; Scott J Fisher; Di Wu; Duane D Miller; James T Dalton
Journal:  Pharm Res       Date:  2006-10-25       Impact factor: 4.200

2.  Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration.

Authors:  Mami Ogita; Marie Therese Rached; Elzbieta Dworakowski; John P Bilezikian; Stavroula Kousteni
Journal:  Endocrinology       Date:  2008-07-10       Impact factor: 4.736

Review 3.  Sex hormones, their receptors and bone health.

Authors:  K Venken; F Callewaert; S Boonen; D Vanderschueren
Journal:  Osteoporos Int       Date:  2008-04-05       Impact factor: 4.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.